Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biomarkers in patients with acute dyspnoea: what for?
Brunner-La Rocca HP, Sanders-van Wijk S, Knackstedt C. Brunner-La Rocca HP, et al. Eur Heart J. 2012 Sep;33(17):2124-6. doi: 10.1093/eurheartj/ehs212. Epub 2012 Jul 17. Eur Heart J. 2012. PMID: 22807467 No abstract available.
Multimarker strategy for short-term risk assessment in patients with dyspnea in the emergency department: the MARKED (Multi mARKer Emergency Dyspnea)-risk score.
Eurlings LW, Sanders-van Wijk S, van Kimmenade R, Osinski A, van Helmond L, Vallinga M, Crijns HJ, van Dieijen-Visser MP, Brunner-La Rocca HP, Pinto YM. Eurlings LW, et al. J Am Coll Cardiol. 2012 Oct 23;60(17):1668-77. doi: 10.1016/j.jacc.2012.06.040. Epub 2012 Sep 26. J Am Coll Cardiol. 2012. PMID: 23021334 Free article.
Safety and tolerability of intensified, N-terminal pro brain natriuretic peptide-guided compared with standard medical therapy in elderly patients with congestive heart failure: results from TIME-CHF.
Sanders-van Wijk S, Muzzarelli S, Neuhaus M, Kiencke S, Maeder M, Estlinbaum W, Tobler D, Mayer K, Erne P, Pfisterer ME, Brunner-La Rocca HP; TIME-CHF investigators. Sanders-van Wijk S, et al. Eur J Heart Fail. 2013 Aug;15(8):910-8. doi: 10.1093/eurjhf/hft079. Epub 2013 May 10. Eur J Heart Fail. 2013. PMID: 23666681 Free article. Clinical Trial.
Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S, Maeder MT, Nietlispach F, Rickli H, Estlinbaum W, Erne P, Rickenbacher P, Peter M, Pfisterer MP, Brunner-La Rocca HP; TIME-CHF Investigators. Sanders-van Wijk S, et al. Circ Heart Fail. 2014 Jan;7(1):131-9. doi: 10.1161/CIRCHEARTFAILURE.113.000527. Epub 2013 Dec 18. Circ Heart Fail. 2014. PMID: 24352403 Free article. Clinical Trial.
Heart failure and COPD: time to SHIFT?
Sanders-van Wijk S, van Empel V, Knackstedt C, Brunner-La Rocca HP. Sanders-van Wijk S, et al. Int J Cardiol. 2014 Mar 15;172(2):293-4. doi: 10.1016/j.ijcard.2013.12.285. Epub 2014 Jan 10. Int J Cardiol. 2014. PMID: 24452222 No abstract available.
Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure).
Sanders-van Wijk S, van Asselt AD, Rickli H, Estlinbaum W, Erne P, Rickenbacher P, Vuillomenet A, Peter M, Pfisterer ME, Brunner-La Rocca HP; TIME-CHF Investigators. Sanders-van Wijk S, et al. JACC Heart Fail. 2013 Feb;1(1):64-71. doi: 10.1016/j.jchf.2012.08.002. Epub 2013 Feb 4. JACC Heart Fail. 2013. PMID: 24621800 Free article. Clinical Trial.
Risk stratification with the use of serial N-terminal pro-B-type natriuretic peptide measurements during admission and early after discharge in heart failure patients: post hoc analysis of the PRIMA study.
Eurlings LW, Sanders-van Wijk S, van Kraaij DJ, van Kimmenade R, Meeder JG, Kamp O, van Dieijen-Visser MP, Tijssen JG, Brunner-La Rocca HP, Pinto YM. Eurlings LW, et al. J Card Fail. 2014 Dec;20(12):881-90. doi: 10.1016/j.cardfail.2014.08.014. Epub 2014 Aug 28. J Card Fail. 2014. PMID: 25175696 Free article. Clinical Trial.
Osteoglycin prevents cardiac dilatation and dysfunction after myocardial infarction through infarct collagen strengthening.
Van Aelst LN, Voss S, Carai P, Van Leeuwen R, Vanhoutte D, Sanders-van Wijk S, Eurlings L, Swinnen M, Verheyen FK, Verbeken E, Nef H, Troidl C, Cook SA, Brunner-La Rocca HP, Möllmann H, Papageorgiou AP, Heymans S. Van Aelst LN, et al. Circ Res. 2015 Jan 30;116(3):425-36. doi: 10.1161/CIRCRESAHA.116.304599. Epub 2014 Dec 17. Circ Res. 2015. PMID: 25520363
42 results